SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2001
GUILFORD PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)| | | | | |
| Delaware | | 0-23736 | | 52-1841960 |
| |
| |
|
(State or other jurisdiction of
incorporation or organization) | | (Commission File
Number) | | (I.R.S. Employer
Identification No.) |
| | | | | |
6611 Tributary Street
Baltimore, Maryland | | | | 21224 | |
|
|
|
|
|
| (Address of principal executive offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: (410) 631-6300
(Former name or former address, if changed since last report)
Exhibit Index is on page 4.
INFORMATION TO BE INCLUDED IN THE REPORT
Item 5. Other Events
Guilford Pharmaceuticals Inc. announced today that Amgen Inc. has completed a Phase II clinical trial of NIL-A, the neuroimmunophilin ligand licensed to it by Guilford Pharmaceuticals, in patients with Parkinson’s disease. This trial is the first clinical evaluation of a neuroimmunophilin ligand in the treatment of Parkinson’s disease. A press release containing additional information was issued today and is attached hereto as Exhibit 99.1
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | | GUILFORD PHARMACEUTICALS INC. |
| | | | |
| Dated: | July 26, 2001 | | By: | /s/ Thomas C. Seoh
Thomas C. Seoh
Vice President, General Counsel and
Secretary |
- 3 -
INDEX TO EXHIBITS
| | | | | | | |
| Exhibit |
|
| Number | | Exhibit Description | | Page |
| |
| |
|
| 99.1 | | Press Release dated July 26, 2001 | | | 5 | |
- 4 -
